Development and validation of a risk-prediction model for adverse drug reactions in real-world cancer patients treated with anlotinib
We developed and validated a simple model to use the ADR risk score in patients who were administered anlotinib. This risk prediction model was well-calibrated and discriminative. It can be used as a reference for clinical decision-making. It has clinical significance for preventing ADRs, improving the prognosis of patients, and providing support for the rational use of drugs.
Authors
- Jiyong Liu (ORCID: https://orcid.org/0000-0003-0444-957X)
- Jiajia Qian (ORCID: https://orcid.org/0000-0002-8579-8351)
- Yunyun Cai
- Wenjun Yi (ORCID: https://orcid.org/0000-0002-1563-4925)
- Cong Ruan
- Rui Xu (ORCID: https://orcid.org/0009-0008-4946-4777)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1177/20420986251328687
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05